CLAIMS for EP, BR, CA, CO, CN, CZ, HU, ID, IL, IN, KR, MX, NO, PL, SG, SK and ZA

1. A pharmaceutical composition comprising as active ingredients N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof in combination with an HMG-CoA reductase inhibitor.

2. The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin, atorvastatin, rosuvastatin or pitavastatin.

3. The pharmaceutical composition according to claim 2 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.

4. The pharmaceutical composition according to claim 3 wherein the HMG-CoA reductase inhibitor is pravastatin, atorvastatin or pitavastatin.

5. The pharmaceutical composition according to claim 4 wherein the HMG-CoA reductase inhibitor is pravastatin or atorvastatin.

6. The pharmaceutical composition according to claim 5 wherein the HMG-CoA reductase inhibitor is pravastatin.

7. The pharmaceutical composition according to claim 5 wherein the HMG-CoA reductase inhibitor is atorvastatin.

8. The pharmaceutical composition according to any one of claims 1 to 7 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

9. The pharmaceutical composition according to claim 1 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is pravastatin.

10. The pharmaceutical composition according to claim 1 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is atorvastatin.

11. The pharmaceutical composition according to any one of claims 1 to 10, formulated for simultaneous, separate or sequential administration of the active ingredients.

12. The pharmaceutical composition according to claim 11, formulated for simultaneous administration of the active ingredients.

13. The pharmaceutical composition according to claim 11, formulated for separate or sequential administration of the active ingredients.

14. A kit including a plurality of containers in which at least one of said containers contains N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof and at least one different container contains an HMG-CoA reductase inhibitor.

15. The kit according to claim 14 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin, atorvastatin, rosuvastatin or pitavastatin.

16. The kit according to claim 15 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.

17. The kit according to claim 16 wherein the HMG-CoA reductase inhibitor is pravastatin, atorvastatin or pitavastatin.

18. The kit according to claim 17 wherein the HMG-CoA reductase inhibitor is pravastatin or atorvastatin.

19. The kit according to claim 18 wherein the HMG-CoA reductase inhibitor is pravastatin.

20. The kit according to claim 19 wherein the HMG-CoA reductase inhibitor is atorvastatin.

21. The kit according to any one of claims 14 to 20 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

22. The kit according to claim 14 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is pravastatin.

23. The kit according to claim 14 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is atorvastatin.

24. The use of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use, in combination with an HMG-CoA reductase inhibitor, in the prevention or treatment of atherosclerosis.

25. The use according to claim 24 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin, atorvastatin, rosuvastatin or pitavastatin.

26. The use according to claim 25 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.

27. The use according to claim 26 wherein the HMG-CoA reductase inhibitor is pravastatin, atorvastatin or pitavastatin.

28. The use according to claim 27 wherein the HMG-CoA reductase inhibitor is pravastatin or atorvastatin.

29. The use according to claim 28 wherein the HMG-CoA reductase inhibitor is pravastatin.

30. The use according to claim 28 wherein the HMG-CoA reductase inhibitor is atorvastatin.

31. The use according to any one of claims 24 to 30 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

32. The use according to claim 24 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is pravastatin.

33. The use according to claim 24 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is atorvastatin.

34. The use of a composition as defined in any one of claims 1 to 13 in the manufacture of a medicament for use in the prevention or treatment of atherosclerosis.

35. The use of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use, in combination with an HMG-CoA reductase inhibitor, in the prevention or treatment of xanthoma.

36. The use according to claim 35 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin, atorvastatin, rosuvastatin or pitavastatin.

37. The use according to claim 36 wherein the HMG-CoA reductase inhibitor is pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.

38. The use according to claim 37 wherein the HMG-CoA reductase inhibitor is pravastatin, atorvastatin or pitavastatin.

39. The use according to claim 38 wherein the HMG-CoA reductase inhibitor is pravastatin or atorvastatin.

40. The use according to claim 39 wherein the HMG-CoA reductase inhibitor is pravastatin.

41. The use according to claim 40 wherein the HMG-CoA reductase inhibitor is atorvastatin.

42. The use according to any one of claims 35 to 41 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

43. The use according to claim 35 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is pravastatin.

44. The use according to claim 35 wherein the pharmacologically acceptable salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate and the HMG-CoA reductase inhibitor is atorvastatin.

45. The use of a composition as defined in any one of claims 1 to 13 in the manufacture of a medicament for use in the prevention or treatment of xanthoma.